arrow
J

Jason Aldred

selkirk neurology and inland northwest research
H指数:19
被引数:2,046

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials

在晚期帕金森病中使用Foslevodopa/Foscarbidopa改善运动一致性和稳定性:两项III期临床试验的回顾性分析

2025-10-040
OA
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

帕金森病患者中左旋多巴/卡比多巴福斯汀单药治疗的有效性和安全性

2025-07-300
OA
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study

基因靶向试验时代基因检测的相关性: 罗斯托克帕金森病研究

BRAIN
IF11.7
2024-08-018
OAAI
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (vol 12, 1937, 2023)

连续皮下注射Foslevodopa/Foscarbidopa治疗帕金森氏病: 安全性和有效性来自12个月,单臂,开放标签,3期研究的结果 (第12卷,1937,2023)

2023-10-100
OAAI
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Aug, 10.1007/s40120-023-00533-1, 2023)

连续皮下注射Foslevodopa/Foscarbidopa治疗帕金森病: 一项为期12个月,单臂,开放标签,3期研究的安全性和有效性结果 (8月,10.1007/s40120-023-00533-1,2023)

2023-08-2637
OAAI
Image-Guided Programming Tool for DBS Programming Used with a Multiple-Source, Constant-Current System Reduces Initial Programming Time
2023-04-250
PRE
Real-World Outcomes in USA using DBS Systems with Directionality and Multiple Independent Current Control
2023-04-250
PRE
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease
2022-06-08120
PRE
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses

卡比多巴/左旋多巴肠内混悬液与口服卡比多巴/左旋多巴治疗晚期帕金森病的日常运动症状控制模式: 临床试验事后分析

2022-02-222
OAAI
Sustained improvements in motor and non-motor symptoms in advanced Parkinson's disease patients treated with carbidopa levodopa enteral suspension in a 'real-world' study
2021-10-010
PRE
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
2021-09-1498
OA